ArticleDermatology and therapy2024

Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Difamilast 1% and Delgocitinib 0.5% in Patients with Moderate-to-Severe Atopic Dermatitis.

Takeshi Nakahara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.